Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?
作者信息
Ghafouri Sanaz, Timmerman John, Larson Sarah, Mead Monica D
机构信息
Department of Hematology Oncology, UCLA Medical Center, 757 Westwood Plaza, Los Angeles, CA, 90095, USA.
UCLA Lymphoma Program, Division of Hematology & Oncology, Department of Medicine, UCLA Medical Center, 757 Westwood Plaza, Los Angeles, CA, 90095, USA.
出版信息
Bone Marrow Transplant. 2021 Apr;56(4):974-977. doi: 10.1038/s41409-020-01099-4. Epub 2020 Nov 10.
Abstract
摘要
相似文献
1
Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?
Bone Marrow Transplant. 2021 Apr;56(4):974-977. doi: 10.1038/s41409-020-01099-4. Epub 2020 Nov 10.
2
Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
Leuk Lymphoma. 2018 Aug;59(8):1785-1796. doi: 10.1080/10428194.2017.1387905. Epub 2017 Oct 23.
3
Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Clin Lymphoma Myeloma Leuk. 2019 Dec;19(12):751-757. doi: 10.1016/j.clml.2019.09.598. Epub 2019 Oct 2.
4
Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
Clin Lymphoma Myeloma Leuk. 2023 Jan;23(1):15-21. doi: 10.1016/j.clml.2022.09.008. Epub 2022 Oct 7.
5
Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.
JAMA Oncol. 2020 Feb 1;6(2):281-290. doi: 10.1001/jamaoncol.2019.3869.
6
Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis.
J Hematol Oncol. 2020 Jan 3;13(1):1. doi: 10.1186/s13045-019-0838-y.
7
Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
Ann Pharmacother. 2021 Mar;55(3):390-405. doi: 10.1177/1060028020944233. Epub 2020 Jul 22.
8
Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.
Am J Hematol. 2019 May;94(S1):S18-S23. doi: 10.1002/ajh.25403. Epub 2019 Jan 24.
9
Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
Curr Oncol Rep. 2019 Mar 27;21(5):38. doi: 10.1007/s11912-019-0789-z.
10
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
Blood. 2018 Aug 23;132(8):777-781. doi: 10.1182/blood-2018-04-839217. Epub 2018 Jun 18.
引用本文的文献
1
CAR-T Cells for the Treatment of Central Nervous System Tumours: Known and Emerging Neurotoxicities.
Brain Sci. 2024 Nov 30;14(12):1220. doi: 10.3390/brainsci14121220.
2
The contemporary spectrum of radiotherapy for hematologic malignancies involving the central nervous system: From focal therapy to craniospinal.
Semin Radiat Oncol. 2025 Jan;35(1):126-137. doi: 10.1016/j.semradonc.2024.11.001.
3
Clinical outcomes of chimeric antigen receptor T-cell therapy following autologous hematopoietic stem cell transplantation in 38 patients with refractory/relapsed primary or secondary central nervous system lymphoma.
Cancer Immunol Immunother. 2024 Nov 11;74(1):17. doi: 10.1007/s00262-024-03855-7.
4
CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma.
Exp Hematol Oncol. 2024 Oct 13;13(1):100. doi: 10.1186/s40164-024-00538-y.
5
Updates of primary central nervous system lymphoma.
Ther Adv Hematol. 2024 Jun 12;15:20406207241259010. doi: 10.1177/20406207241259010. eCollection 2024.
6
CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas.
Blood Adv. 2024 Oct 8;8(19):5192-5199. doi: 10.1182/bloodadvances.2024013393.
7
Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis.
Br J Haematol. 2024 Sep;205(3):1202-1207. doi: 10.1111/bjh.19569. Epub 2024 May 26.
8
Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells.
Cancer Immunol Immunother. 2024 Feb 13;73(3):45. doi: 10.1007/s00262-023-03619-9.
9
Sustained efficacy of chimeric antigen receptor T-cell therapy in central nervous system lymphoma: a systematic review and meta-analysis of individual data.
Front Pharmacol. 2024 Jan 24;14:1331844. doi: 10.3389/fphar.2023.1331844. eCollection 2023.
10
Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions.
Cancers (Basel). 2023 Dec 21;16(1):46. doi: 10.3390/cancers16010046.
本文引用的文献
1
CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia.
Clin Adv Hematol Oncol. 2016 Oct;14(10):802-808.
Zotero 插件